The exact mechanism of action of these drugs is not clear. All the DMARD's The inhibiting release or reduce the effectiveness of inflammatory cytokines. Where that activated T lymphocytes, especially very important in this process are known to both methotrexate the, livlonomid and cyclosporine inhibit T lymphocytes. Cytokines, which appear to be important in the inflammatory cascade, including the (TNF )
And intrulyukinat IL-1, IL-2 and IL-6 . And there is good evidence that all DMARD's The inhibition of cytokines in both glass and bio in the middle. livlonomid inhibits the proliferation of B-cells and thus inhibits the production Antibiotics. Many vital treatments designed to target T lymphocytes and a specific pattern of cytokines.
The latest of these studies used in experimental treatments as counter for TNF agents This includes monoclonal antibiotic Alanfliximap and amending the effectiveness of the TNF And TNF receptors Dissolved itanersept and which in turn is linked to Pal TNF And gives the boat ineffective vital.
Hadat the IL-1 Also being developed for use in the treatment of rheumatic fever.
